Revivo BioSystems is a biotechnology company that has developed a microfluidic tissue culture system capable of mimicking blood flow, primarily for skin applications such as biopsies and reconstructed tissues.
This technology improves the reliability of skin penetration studies for formulated products in both the cosmetic and pharmaceutical sectors. It also significantly extends the viability of skin biopsies in culture, increasing their lifespan from around 5 days under conventional conditions to up to 20 days with our system.
In parallel, we have developed advanced in vitro models that leverage microfluidic technologies to replicate key biological processes, such as skin aging and wound healing. These platforms enable precise evaluation of compound efficacy. Several of these models have been recognized with awards for their innovation.
1- What made you decide to start this company ?
Since my PhD at the Pasteur Institute, I have realized that progress in certain areas of research and innovation is slowed by the lack of relevant and predictive models. When I discovered what REVIVO BioSystems was developing, I immediately saw a strong opportunity to help accelerate research in these fields.
In addition, the animal-free approach fully aligns with my values and directly addresses a major limitation in the industry, as approximately 95% of preclinical results fail to translate effectively to humans.
2- What are you most proud of since launching ?
After launching ReleGO, our microfluidic platform, I am most proud of developing biological models that fully leverage this technology to improve research efficiency. In particular, the standardized pre-wounded skin model stands out. This in vitro model is capable of autonomous healing and offers a credible alternative to animal models, which have so far been the gold standard for this type of study.
I am convinced that this model has the potential to become a new gold standard in the future, and we are fully committed to driving its adoption.
3- How do you see La French Tech Singapore contributing to the success of founders like you ?
La French Tech Singapore can clearly serve as a strong accelerator for founders like us by bridging ecosystems. For a biotech company, entering Singapore and more broadly Southeast Asia is highly strategic, especially when it comes to partnerships, regulatory aspects, and local validation.
We are currently launching our biological models as products in Asia, and soon in Europe, and we believe La French Tech can play a key role in supporting this expansion.
What really makes the difference is the network. Being connected to other founders, investors, corporates, and research institutions helps move much faster and unlock opportunities that would otherwise take a lot of time to access.
There is also a strong impact on visibility and credibility. Having the support of La French Tech Singapore can help to build trust with local partners and clients, which is essential when entering a new market.
4- What type of opportunity are you looking to unlock next ?
We are currently raising funds and seeking a lead investor to support us in expanding our presence in Europe and the US, entering additional markets such as the pharmaceutical industry, and contributing to the development and commercialization of the new hardware we are building.
Interview of Sebastien TEISSIER, Founder of Revivo BioSystems